Cartalax vs Chonluten
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Ala-Glu-Asp, AED Tripeptide
Cartalax is a synthetic tripeptide (Ala-Glu-Asp, or AED) from the Khavinson family of short peptide bioregulators, studied as a cartilage and connective-tissue regulator. It is a research compound, not an approved drug, and no registered human clinical trials exist.
Also: Glu-Asp-Gly, EDG
Chonluten is a synthetic tripeptide (Glu-Asp-Gly, EDG) from the Khavinson bioregulator family, pitched as the lung and bronchial peptide, derived conceptually from the same program that produced Epitalon and Cortagen. It is researched for respiratory tissue and age-related lung decline, and it has no FDA or EMA approval. The evidence is essentially all preclinical or uncontrolled Russian clinical observation, with no randomized human trials.
Key Comparison Insights
- Both peptides belong to the Bioregulators category, suggesting similar primary applications.
Detailed Comparison
| Attribute | Cartalax | Chonluten |
|---|---|---|
| Category | Bioregulators | Bioregulators |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Cartalax belongs to the cytogen class of short peptides. The Khavinson research group proposes that AED regulates tissue-specific gene expression in cartilage cells, upregulating chondrogenic genes such as SOX9, type II collagen (COL2) and aggrecan (ACAN), rather than acting through classical receptor signaling. This DNA-binding, gene-regulation model is a peer-reviewed hypothesis supported mainly by the group's own in-vitro work, not independently established mainstream consensus. | Like the other Khavinson peptides, Chonluten is proposed to act not through a classic receptor but by entering cells, reaching the nucleus, and binding short stretches of DNA to tune gene expression in its target tissue, here the respiratory epithelium. The claimed effect is restoring more normal patterns of stress-response, antioxidant and inflammation-related gene activity in bronchial and lung cells as they age or are damaged. Whether a free tripeptide actually reaches the nucleus at meaningful concentrations and binds specific promoters in humans remains an open, single-school hypothesis rather than an established pathway. Read the gene-regulation story as a proposed model, not a proven drug mechanism. |
| Common Dosing | Limited community data available See research protocols | 10-20 mg daily Once or twice daily |
| Administration | Oral | Oral capsules or sublingual |
| Typical Duration | 10-30 day courses | 10-30 day cycles |
| Best Time to Take | Morning or as directed | Morning on empty stomach |
Possible Side Effects May vary by individual |
|
|
| Research Summary | The published evidence is in vitro and animal only. A 2023 review of peptide regulation of chondrogenic differentiation lists AED among peptides that act on cartilage cells through WNT, ERK-p38 and Smad signaling, while stating plainly that no human clinical trials exist. The broader Russian literature reports cartilage-protective and matrix-synthesis effects, but independent Western validation is limited. Bottom line: the mechanism is plausible and supported in cell models, but human efficacy is unproven. | Chonluten (the EDG tripeptide) shows up in Khavinson-group work on bronchopulmonary tissue, including a 2020 review in which his team states that oral EDG improved a physical-performance index and was used in the setting of chronic bronchitis with an asthmatic component (Khavinson et al., 2020). That same line of work pairs it with the related tetrapeptide Bronchogen (AEDL) for chronic obstructive pulmonary disease. The problem is that nearly all of this originates from one institute and its affiliated labs, the clinical observations are uncontrolled and not independently replicated, and there are no registered randomized controlled trials. Mechanistic claims about gene expression in respiratory cells come from cell-culture and animal models, not human outcome data. So Chonluten sits in the same bucket as most Khavinson peptides: an interesting tissue-specific hypothesis with real institutional research behind it, but no rigorous human proof that it does anything for lung disease. |
Frequently Asked Questions: Cartalax vs Chonluten
What is the difference between Cartalax and Chonluten?
Cartalax is a bioregulators peptide that cartalax is a synthetic tripeptide (ala-glu-asp, or aed) from the khavinson family of short peptide bioregulators, studied as a cartilage and connective-tissue regulator. it is a research compound, not an approved drug, and no registered human clinical trials exist. Chonluten is a bioregulators peptide that chonluten is a synthetic tripeptide (glu-asp-gly, edg) from the khavinson bioregulator family, pitched as the lung and bronchial peptide, derived conceptually from the same program that produced epitalon and cortagen. it is researched for respiratory tissue and age-related lung decline, and it has no fda or ema approval. the evidence is essentially all preclinical or uncontrolled russian clinical observation, with no randomized human trials. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Cartalax or Chonluten?
Neither is universally "better" - the choice depends on your specific goals. Cartalax is typically used for bioregulators purposes, while Chonluten is used for bioregulators. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Cartalax and Chonluten be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Cartalax and Chonluten together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.